

**ACTIVATION OF MACROPHAGE TUMORICIDAL ACTIVITY BY
GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR**

Patent Number: ☐ US5078996
Publication date: 1992-01-07
Inventor(s): CONLON III PAUL J (US); GRABSTEIN KENNETH H (US)
Applicant(s): IMMUNEX CORP (US)
Requested Patent: ☐ JP62089621
Application Number: US19860888995 19860731
Priority Number (s): US19860888995 19860731; US19850766893 19850816
IPC Classification: A61K37/66; A61K45/05
EC Classification: C07K14/535
Equivalents: AU586876, AU6103186, DE3685918D, DE3685918T, ☐ DK382986, ☐ EP0211684, A3, B1, JP2043817C, JP7080781B

Abstract

Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be treated by direct administration of therapeutically effective quantities of activated granulocyte-macrophage colony stimulating factor. Homogeneous granulocyte-macrophage colony stimulating factor for use in activating macrophages and monocyte precursors is prepared by recombinant DNA techniques. The gene coding for granulocyte-macrophage colony stimulating factor is isolated and then recombinant protein product expressed in an appropriate expression system. The granulocyte-macrophage colony stimulating factor recovered from the expression system is purified to homogeneity by reverse phase high-performance liquid chromatography.

Data supplied from theesp@cenettest database - I2

CSF SUSTAINED RELEASE PHARMACEUTICAL

Patent Number: JP62230729
Publication date: 1987-10-09
Inventor(s): FUJIOKA TAKAHARU; others: 02
Applicant(s): SUMITOMO PHARMACEUT CO
Requested Patent: ☐ JP62230729
Application: JP19860185437 19860806
Priority Number(s):
IPC Classification: A61K37/04
EC Classification:
Equivalents: JP1999987C, JP7025688B

Abstract

PURPOSE:A CSF sustained release pharmaceutical, obtained by containing a colony stimulating factor (CSF) in a specific carrier, e.g. collagen, gelatin, etc., useful for recovering granulocytopenia in leukocytes, cancer, etc., and capable of sustaining release for a long period.
CONSTITUTION:A CSF sustained release pharmaceutical obtained by blending, e.g. an aqueous solution of a colony stimulating factor (CSF) with an aqueous solution of a carrier, capable of in vivo administration and consisting of a low toxic compound, preferably collagen, gelatin or a mixture thereof, concentrating and drying the resultant blend. Thus, the CSF is entrapped in the carrier. The resultant material is then suitably processed depending on the purpose. For example, the material is pulverized to an injectable particle diameter while cooling with dry ice, etc., and suspended in a solvent for injection to afford a sustained release suspension type injection. Alternatively, the material is molded into a spherical, cylindrical shape, etc., and can be administered by a method of in vivo imbedding, intracoeelomic inserting, etc. Multipotential SCF, granulocytic SCF, etc., are cited as the CSF.

Data supplied from the esp@cenet database - I2